HC Wainwright Has Strong Forecast for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued to investors on Monday, November 10th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($3.18) per share for the year, up from their previous estimate of ($3.88). HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2025 earnings at ($0.89) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.87) EPS, FY2027 earnings at ($4.07) EPS, FY2028 earnings at ($4.67) EPS and FY2029 earnings at ($2.70) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.

DNTH has been the topic of several other research reports. Guggenheim lifted their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Wedbush increased their target price on Dianthus Therapeutics from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Stifel Nicolaus increased their price objective on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $63.43.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $36.10 on Wednesday. The company has a fifty day moving average of $35.15 and a 200 day moving average of $25.32. The company has a market capitalization of $1.16 billion, a P/E ratio of -10.37 and a beta of 1.56. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $40.16.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. raised its stake in shares of Dianthus Therapeutics by 53.6% during the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after acquiring an additional 1,000,333 shares in the last quarter. Walleye Capital LLC increased its stake in shares of Dianthus Therapeutics by 29.0% during the first quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock valued at $1,940,000 after buying an additional 24,041 shares during the period. Nuveen LLC bought a new position in Dianthus Therapeutics during the 1st quarter worth about $1,168,000. Vestal Point Capital LP increased its position in Dianthus Therapeutics by 58.1% during the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock valued at $30,839,000 after purchasing an additional 625,069 shares during the period. Finally, Candriam S.C.A. bought a new position in shares of Dianthus Therapeutics during the first quarter valued at approximately $4,510,000. 47.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 16.56% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.